Compound · clinical trials

Tuoyi clinical trials

Also listed in trial records as PD-1 inhibitor

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 49 trials in our China, USA, Spain, Germany, France, Netherlands, Belgium, Japan, South Korea and Australia registers that name Tuoyi as an intervention. Synced 21 Oct 2026

49Current trials

34Recruiting now

27Lead sponsors

10Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 21 Oct 2026 · Editorial standards

At a glance

Tuoyi is named as an intervention in 49 current clinical trials in our China, USA, Spain, Germany, France, Netherlands, Belgium, Japan, South Korea and Australia registers. 34 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Fudan University (7). The most-studied condition is Advanced NSCLC.

Patient leaflets for Tuoyi

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting3469%
Not yet open918%
Active, closed612%

Trials by phase

Phase 22245%
Phase 3714%
Phase 1/2510%
Not applicable510%
Phase 136%
Observational36%
Early Phase 136%
Phase 2/312%

Clinical trials of Tuoyi

49 trials

Study	Phase	Status	Lead sponsor	Registers
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma NCT04997837 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fudan University	China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study NCT05342194 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer NCT06086457 · ClinicalTrials.gov ↗ · Esophageal Neoplasms	Phase 3	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC NCT06627712 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Phase 3	Recruiting	West China Hospital	China
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC NCT06964568 · ClinicalTrials.gov ↗ · Esophageal Carcinoma, Radiotherapy, Immunotherapy	Phase 3	Recruiting	Fudan University	China
RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma NCT07590024 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 3	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT06841679 · Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	Beijing Biostar Pharmaceuticals Co., Ltd	USA, China
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy NCT06084897 · ClinicalTrials.gov ↗ · Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer NCT06281405 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Fudan University	China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment NCT06751849 · ClinicalTrials.gov ↗ · Advanced NSCLC	Phase 2	Recruiting	The First Affiliated Hospital of Nanchang University	China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment NCT06751901 · ClinicalTrials.gov ↗ · Advanced NSCLC	Phase 2	Recruiting	The First Affiliated Hospital of Nanchang University	China
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer NCT06826079 · ClinicalTrials.gov ↗ · Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Sun Yat-sen University	China
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer NCT07007182 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Stomach Neoplasms	Phase 2	Recruiting	Jinbo Yue	China
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients NCT07171606 · ClinicalTrials.gov ↗ · First-line Advanced NSCLC Patients	Phase 2	Recruiting	Shenyang Sunshine Pharmaceutical Co., LTD	China
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study NCT07240194 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma, TP53	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification NCT07417501 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Tongji Hospital	China
Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC NCT07519486 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Sichuan University	China
Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase NCT07555678 · ClinicalTrials.gov ↗ · Anal Squamous Cell Cancer	Phase 2	Recruiting	Fudan University	China
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer NCT07841236 · ClinicalTrials.gov ↗ · Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H)	Phase 2	Recruiting	Fudan University	China
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141 · ClinicalTrials.gov ↗ · Esophageal Cancer (EC)	Phase 2	Recruiting	Sun Yat-sen University	China
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors NCT06144671 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Grit Biotechnology	China
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma NCT07072351 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy	Phase 1/2	Recruiting	West China Hospital	China
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma NCT07182565 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy	Phase 1/2	Recruiting	West China Hospital	China
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment NCT05486650 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Recruiting	Xinqiao Hospital of Chongqing	China
TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment NCT07100405 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Observational	Recruiting	Fudan University	China
Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC NCT07618078 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Observational	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT NCT06622031 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy	Not applicable	Recruiting	Sun Yat-sen University	China
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment NCT06752044 · ClinicalTrials.gov ↗ · Advanced NSCLC	Not applicable	Recruiting	The First Affiliated Hospital of Nanchang University	China
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment NCT06752057 · Advanced NSCLC	Not applicable	Recruiting	The First Affiliated Hospital of Nanchang University	China
First in Human Study of YB1-X7 Injection NCT06889675 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Not applicable	Recruiting	Shanghai Salvectors Biotechnology LTD	China
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors NCT05916248 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Early Phase 1	Recruiting	Ruijin Hospital	China
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer NCT06496373 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable, Chemotherapy-intolerant	Early Phase 1	Recruiting	Ruijin Hospital	China
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia NCT06980155 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Early Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer NCT07551479 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)	Phase 3	Not yet open	Fudan University	China
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT NCT06646666 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma	Phase 2	Not yet open	Ruijin Hospital	China
A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection NCT07142200 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer	Phase 2	Not yet open	RenJi Hospital	China
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study NCT07189793 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder	Phase 2	Not yet open	First Affiliated Hospital of Wenzhou Medical University	China
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma NCT07709533 · ClinicalTrials.gov ↗ · Valid MeSH Conditions	Phase 2	Not yet open	Sun Yat-sen University	China
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma NCT07824856 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases	Phase 2	Not yet open	Sun Yat-sen University	China
Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer NCT07811076 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer (LARC)	Phase 1/2	Not yet open	Xuelei Ma MD	China
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer NCT07154108 · ClinicalTrials.gov ↗ · Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)	Phase 1	Not yet open	Sichuan University	China
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma NCT07500831 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma	Not applicable	Not yet open	Qilu Hospital of Shandong University	China
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma NCT05340270 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor	Phase 2	Active, closed	Guangxi Medical University	China
TIME in Immunotherapy Combined With nCRT for Rectal Cancer NCT05507112 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Peking Union Medical College Hospital	China
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer NCT07791602 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC	Phase 2	Active, closed	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors NCT06710847 · Neoplasms, Colorectal, Solid Tumor, Colon Cancer	Phase 1/2	Active, closed	GlaxoSmithKline	USA, Spain, Netherlands, Belgium, Japan, South Korea, Australia
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC NCT04947241 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 1	Active, closed	Fifth Affiliated Hospital, Sun Yat-Sen University	China
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma NCT05338775 · Relapsed/ Refractory Multiple Myeloma	Phase 1	Active, closed	Janssen Research & Development, LLC	USA, Germany, France, Spain

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Tuoyi

69 conditions

Advanced NSCLC4Immunotherapy3 Neoadjuvant Therapy3 Colon Cancer2 Advanced Solid Tumors2 Gastroesophageal Junction Adenocarcinoma2Hypofractionated Radiotherapy2Hepatocellular Carcinoma2 Gastric Cancer2 Nasopharyngeal Carcinoma (NPC)2 Locally Advanced Rectal Cancer2 Nasopharyngeal Carcinoma2

All 69 conditions

Condition (as registered)	Trials
Advanced NSCLC	4
Immunotherapy	3
Neoadjuvant Therapy	3
Colon Cancer	2
Advanced Solid Tumors	2
Gastroesophageal Junction Adenocarcinoma	2
Hypofractionated Radiotherapy	2
Hepatocellular Carcinoma	2
Gastric Cancer	2
Nasopharyngeal Carcinoma (NPC)	2
Locally Advanced Rectal Cancer	2
Nasopharyngeal Carcinoma	2
Locally Advanced Rectal Cancer (LARC)	2
Relapsed/ Refractory Multiple Myeloma	1
Neoplasms, Colorectal	1
Solid Tumor	1
Rectal Cancer	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Chemotherapy	1
Head and Neck Squamous Cell Carcinoma	1
Locally Advanced Head and Neck Cancer	1
HNSCC	1
Esophageal Cancer	1
Head and Neck Cancer (H&Amp;Amp;Amp;N)	1
Deficient Mismatch Repair	1
Microsatellite Instability-High (MSI-H)	1
Pancreatic Cancer Resectable	1
Chemotherapy-intolerant	1
Esophageal Squamous Cell Carcinoma	1
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	1
Esophageal Neoplasm Metastatic	1
Esophageal Cancer Stage IVb	1
Non-small Cell Lung Cancer (NSCLC)	1
Solid Tumors	1
Gastric Adenocarcinoma	1
Stomach Neoplasms	1
Non Small Cell Lung Cancer	1
Acute Myeloid Leukemia	1
PD-1 Inhibitor	1
B-cell Non Hodgkin Lymphoma	1
Gastric Junction Adenocarcinoma	1
Neoadjuvant Therapies	1
Large B-cell Lymphoma	1
TP53	1
TNBC - Triple-Negative Breast Cancer	1
First-line Advanced NSCLC Patients	1
Anal Squamous Cell Cancer	1
Esophageal Carcinoma	1
Radiotherapy	1
Locally Advanced Head and Neck Squamous Cell Carcinoma	1
Esophageal Cancer (EC)	1
Valid MeSH Conditions	1
Bladder (Urothelial, Transitional Cell) Cancer	1
MSS (Microsatellite Stable)	1
Portal Vein Tumor Thrombus	1
Systemic Therapy	1
Advanced Solid Tumor	1
Esophageal Neoplasms	1
Neoplasm Metastasis	1
Lung Metastases	1
Liver Metastases	1
Intrahepatic Cholangiocarcinoma	1
Carcinoma, Renal Cell	1
Metastatic Renal Cell Carcinoma	1
Advanced Renal Cell Carcinoma	1
Urinary Bladder Neoplasms	1
Carcinoma, Transitional Cell	1
Carcinoma in Situ of Bladder	1
Non-Muscle-Invasive Bladder Cancer	1

By country register

Register	Trials	Recruiting
Clinical trials in China	47	34
Clinical trials in USA	3	1
Clinical trials in Spain	2	0
Clinical trials in Germany	1	0
Clinical trials in France	1	0
Clinical trials in Netherlands	1	0
Clinical trials in Belgium	1	0
Clinical trials in Japan	1	0
Clinical trials in South Korea	1	0
Clinical trials in Australia	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Tuoyi trials

How many clinical trials are testing Tuoyi?

49 current trials in our China, USA, Spain, Germany, France, Netherlands, Belgium, Japan, South Korea and Australia registers name Tuoyi (also registered as PD-1 inhibitor) as a drug or biological intervention, as of the registry sync on 21 October 2026. Completed and withdrawn studies are not counted.

Are Tuoyi trials recruiting patients?

Yes. 34 of the 49 trials are recruiting: 34 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tuoyi clinical trials?

Fudan University (7), Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5), Sun Yat-sen University (5) and The First Affiliated Hospital of Nanchang University (4), among 27 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tuoyi works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tuoyi works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tuoyi (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 21 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.